Resveratrol modulates cocaine-induced inhibitory synaptic plasticity in VTA dopamine neurons by inhibiting phosphodiesterases (PDEs)
Department of Exercise Physiology, Beijing Sport University, Beijing, 100084 China
Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226 USA
Abstract
Resveratrol is a natural phytoalexin synthesized by plants, including grapes. It displays a wide range of neuroprotective benefits associated with anti-aging. Recent studies have shown that resveratrol regulates dopaminergic transmission and behavioral effects of drugs of abuse. The goal of the present study is to investigate whether and how resveratrol alters basal inhibitory synaptic transmission and cocaine-induced inhibitory synaptic plasticity in dopamine neurons of the ventral tegmental area (VTA). We report that resveratrol elevated cAMP levels by itself and further potentiated a forskolin-induced increase in cAMP levels in midbrain slices, consistent with reported effects of inhibition of phosphodiesterases (PDEs). Resveratrol potentiated GABAA and GABAB-mediated inhibitory postsynaptic currents (IPSCs) in VTA dopamine neurons, and these effects were mediated by a protein kinase A (PKA)–dependent enhancement of presynaptic GABA release. In addition, we found that resveratrol blocked endocannabinoid-mediated long-term synaptic depression in VTA dopamine neurons. Resveratrol pretreatments attenuated cocaine-induced conditioned place preference and blocked the cocaine-induced reduction of GABAergic inhibition in VTA dopamine neurons. Together, these results provide evidence that resveratrol modulates basal inhibitory synaptic transmission, cocaine-induced synaptic plasticity, and drug-cue associative learning.
Article notes
Untitled section
Received 2017 Jul 11; Accepted 2017 Nov 6; Collection date 2017.
Introduction
Resveratrol (3,4′,5-trihydroxy-trans-stilbene), a constituent of red wine, produces a wide range of health benefits associated with anti-aging, including protection against type 2 diabetes, obesity, cancer, heart disease, and neurodegenerative diseases1. Since the discovery that resveratrol mimics the life-span extending effects of calorie restriction in budding yeast2, this compound has attracted great interest. However, past research has focused on its role in protecting against aging-related diseases1. Recent studies have shown that resveratrol regulates dopaminergic transmission and behavioral effects of drugs of abuse. Acute resveratrol treatment enhances cocaine-induced increases in dopamine D1 receptor signaling and locomotor activity in mice, presumably via mechanisms involving the inhibition of monoamine oxidases3. In contrast, acute resveratrol treatment is ineffective at altering methamphetamine-induced hyperactivity in mice, while repeated resveratrol treatments decrease methamphetamine-induced hyperactivity in mice and dopamine overflow from rat striatal slices4. There are conflicting reports regarding whether resveratrol alters cocaine-induced conditioned place preference (CPP). Resveratrol has been shown to enhance cocaine CPP by activating the NAD(+)-dependent histone deacetylase sirtuins5. However, another study has shown that resveratrol is ineffective in altering CPP but attenuates cocaine withdrawal-induced anxiety6.
A recent study has identified phosphodiesterases (PDEs) as a direct target for resveratrol, and both resveratrol and the selective PDE4 inhibitor rolipram ameliorate aging-related metabolic phenotypes through inhibition of PDEs7. PDEs are a family of enzymes that hydrolyze intracellular cAMP and cGMP8. There are 11 subtypes of PDEs (PDE1-11), several of which are expressed in the brain9,10. Resveratrol inhibits PDE1, PDE3 and PDE47. PDE1 and PDE3 hydrolyze both cAMP and cGMP, while PDE4 is specific for cAMP9,10. Resveratrol raises both cAMP and cGMP levels in Hela cells7. Non-selective PDE and PDE4-specific inhibitors reduce drug intake and/or drug seeking for psychostimulants, alcohol, and opioids11,12. Selective PDE4 inhibitors such as rolipram significantly reduce cocaine-induced increases in locomotor activity, behavioral sensitization, conditioned place preference (CPP) and self-administration13–17. We have shown that rolipram blocks endocannabinoid-mediated long-term depression of inhibitory synaptic transmission (I-LTD) in dopamine neurons of the ventral tegmental area (VTA)16 and prevents the repeated cocaine treatment-induced imbalance between excitation and inhibition in VTA dopamine neurons17. Although resveratrol has been shown to enhance AMPAR expression via AMP-activated protein kinase-mediated protein translation in cultured neurons18, it was unknown whether resveratrol modulates inhibitory synaptic transmission and plasticity. The present study was undertaken to investigate whether resveratrol regulates GABAA and GABAB receptor-mediated inhibitory postsynaptic currents (IPSCs) in VTA dopamine neurons. In addition, we have shown that endocannabinoid-mediated I-LTD is required for the cocaine-induced reduction of GABAergic inhibition to VTA dopamine neurons19,20. We therefore examined whether resveratrol modulates I-LTD. Finally, we investigated whether systemic administration of resveratrol altered cocaine-induced CPP and reduction of GABAergic inhibition in VTA dopamine neurons.
Results
Resveratrol increased cAMP levels in the VTA
Resveratrol was recently found to be a non-selective PDE inhibitor (inhibition of PDE1, 3, 4)7, while rolipram is a selective PDE4 inhibitor. We determined whether resveratrol increased cAMP levels in the VTA. VTA slices were treated with vehicle, resveratrol (100 µM), rolipram (1 µM) and/or the adenylyl cyclase activator forskolin (10 µM) for 30 min. They were then washed, frozen in liquid nitrogen, and homogenized. cAMP levels were measured using an ELISA kit (Enzo). A two-way ANOVA showed that forskolin (F (1,52) = 244.05, p < 0.001) and the PDE inhibitors (F (2,52) = 34.13, p < 0.001) significantly increased cAMP levels, and there was a significant interaction between forskolin and PDE inhibitors (F (2, 52) = 4.14, p = 0.021). Tukey’s post-hoc tests indicated that resveratrol (Resv) (p < 0.001) or rolipram (p < 0.001) significantly increased cAMP levels and further potentiated the forskolin-induced increase in cAMP levels (p < 0.001; Fig. 1). The latter finding suggests that resveratrol and forsklin increase cAMP via distinct mechanisms. These results are consistent with previous findings that resveratrol is a PDE inhibitor7.
Resveratrol potentiated GABAA receptor-mediated IPSCs
We examined the effects of resveratrol on GABAA receptor-mediated IPSCs in VTA dopamine neurons. To isolate GABAA receptor-mediated IPSCs, the glutamate receptor antagonists CNQX (20 µM) and D-AP5 (50 µM) and the GABAB receptor antagonist CGP 55845 (1 µM) were present in the ACSF throughout the experiments. IPSCs were evoked by paired-pulse stimulation with an inter-pulse interval of 50 ms. Bath application of resveratrol (100 µM) caused a significant increase in the amplitude of IPSCs (129.46 ± 9.49% of baseline, t 9 = 3.018, p = 0.015; Fig. 2a). The enhancement of IPSC amplitude was accompanied by a decrease in the paired-pulse ratio (PPR) (t 9 = 2.747, p = 0.023; Fig. 2b). The PPR was calculated as the ratio of the amplitude of the second IPSCs to that of the first IPSCs. The decrease in the PPR suggests an increase in the probability of presynaptic GABA release21. Bath application of resveratrol at a low concentration (10 µM) had no significant effect on the amplitude of IPSCs (98.01 ± 2.17% of baseline, t 5 = 1.077, p = 0.331) and the PPR (t 5 = 0.394, p = 0.710; Supplementary Fig. S1). One possibility is that PDE expression in the VTA may be low, perhaps requiring higher concentrations of resveratrol to affect IPSCs.
It has been shown that activating cAMP/PKA signaling enhances neurotransmitter release at many excitatory and inhibitory synapses22–25. Next, we examined whether PKA was involved in the resveratrol-induced increase in IPSC amplitude. The PKA inhibitor H-89 (10 µM) was present in the ACSF throughout the experiment. The effects of resveratrol on IPSCs were blocked in the continuous presence of H-89 (93.08 ± 5.67% of baseline, t 14 = 2.768, p = 0.015 vs. resveratrol alone; Fig. 2a). These results suggest resveratrol potentiates GABAA-mediated IPSCs via an enhancement of cAMP/PKA signaling.
Resveratrol is a competitive, reversible inhibitor of PDEs7. We tested whether the resveratrol-induced enhancement of GABAA-IPSCs could be reversed upon washout. After stable baseline recordings of IPSCs for 10 min, resveratrol (100 µM) was applied for 20 min, which was followed by a 20 min washout. Consistent with the earlier observation in Fig. 2, we found that resveratrol application enhanced IPSCs (135.88 ± 7.68% of baseline, t 6 = 7.678, p < 0.001; Supplementary Fig. S2). However, the potentiation of IPSCs was not reversed after 20 min of washout (139.72 ± 7.19% of baseline, t 6 = 1.876, p = 0.110 vs. resveratrol application; Supplementary Fig. S2). Our past experience indicates that pharmacological effects of many lipophilic compounds such as cannabinoid CB1 receptor agonists and antagonists are not reversible due to poor washout from brain slices19. The difficulty to wash out resveratrol from brain slices may explain why the effect of resveratrol on IPSCs was not reversed during the time window tested.
Resveratrol blocked I-LTD in VTA dopamine neurons
We have shown that a pathophysiologically relevant concentration of cocaine (3 µM) enables subthreshold stimulation to induce I-LTD in VTA dopamine neurons of midbrain slices19, and that such I-LTD is mediated by activation of the D2 receptor and the CB1 receptor, followed by subsequent inhibition of cAMP/PKA signaling20,26. Having shown that resveratrol enhanced the amplitude of GABAA receptor-mediated IPSCs, we next examined whether resveratrol affected I-LTD in VTA dopamine neurons. Whole-cell voltage-clamp recordings (holding potential −70 mV) were made from VTA dopamine neurons. IPSCs were evoked by stimulating inhibitory synaptic afferents at 0.1 Hz. The AMPA receptor antagonist CNQX (20 µM), the NMDA receptor antagonist AP-5 (50 µM), and the GABAB receptor antagonist CGP 55845 (1 µM) were present in the ACSF throughout the experiments. Consistent with our previous studies16,19,20, we found that repeated synaptic stimulation (10 Hz, 5 min) in the presence of a low concentration of cocaine (3 µM) induced I-LTD (73.12 ± 5.34% of baseline, t 12 = 5.069, p < 0.001; Fig. 2c). This I-LTD was blocked by the continuous presence of resveratrol (100 µM) (95.89 ± 3.40% of baseline, t 11 = 3.456, p = 0.005 vs. control; Fig. 2c). These results indicate that resveratrol blocked I-LTD induction in VTA dopamine neurons.
Resveratrol potentiated GABAB receptor-mediated IPSCs
GABAB receptors are linked to G protein-gated inwardly-rectifying potassium (GIRK) channels27. Repetitive, short-burst electrical stimulation induces GABAB receptor-mediated slow IPSCs in VTA dopamine neurons28. Next, we examined the effect of resveratrol on GABAB receptor-mediated IPSCs in VTA dopamine neurons. Whole-cell recordings were made from VTA dopamine neurons at a holding potential of −55 mV. GABAB receptor-mediated IPSCs were evoked with five stimuli (0.3 ms) at 50 Hz and were isolated pharmacologically with GABAA receptor blocker picrotoxin (100 μM), AMPAR antagonist CNQX (10 μM), NMDAR blocker MK-801 (10 μM), D2 dopamine receptor antagonist sulpiride (1 μM), and group I mGluR antagonist CPCCOEt (100 µM) in the ACSF. We found that bath application of resveratrol (100 μM) enhanced the amplitude of GABAB receptor-mediated IPSCs in VTA dopamine neurons (128.00 ± 5.70% of baseline, t 8 = 9.311, p < 0.001 vs. baseline; Fig. 3a,c). The IPSCs were blocked by the selective GABAB receptor antagonist CGP 55845 (1 μM) (Fig. 3a), indicating that they are indeed GABAB-mediated IPSCs. In the presence of the PKA inhibitor H89 (10 µM), bath application of resveratrol (100 µM) did not significantly alter GABAB-mediated IPSCs (94.47 ± 1.72% of baseline, t 8 = 18.42, p < 0.001 vs. resveratrol alone; Fig. 3b,c). Thus, resveratrol potentiated both GABAA- and GABAB-mediated IPSCs via cAMP/PKA-dependent mechanisms.
The effects of resveratrol pretreatments on the acquisition of cocaine CPP
We have shown that pretreatments with the selective PDE4 inhibitor roplipram 30 min before place conditioning attenuates cocaine CPP in rats16 and cocaine-induced locomotor sensitization in mice17. We examined whether pretreatments with resveratrol before place conditioning affected the acquisition of cocaine CPP. Mice underwent cocaine or saline conditioning as described in Materials and Methods and the timeline of the experimental design is shown in Fig. 4a. Mice did not show unconditioned place preference in the pre-test (p > 0.05, Fig. 4b). Resveratrol (20 mg/kg, i.p.) or vehicle was i.p. injected 30 min before each cocaine or saline pairing on all conditioning days. We found that cocaine (15 mg/kg) conditioning (F (1,24) = 120.32, p < 0.001) and resveratrol pretreatments (F (1,24) = 13.96, p = 0.001) significantly altered the preference score, and there was a significant interaction between cocaine conditioning and resveratrol pretreatments (F (1,24) = 10.48, p = 0.004). Tukey’s post hoc tests indicated that cocaine conditioning induced CPP in vehicle-pretreated mice (p < 0.001), while resveratrol pretreatments significantly attenuated cocaine CPP (p < 0.001; Fig. 4c).
Resveratrol pretreatments blocked the reduction of GABAergic inhibition induced by cocaine conditioning
We and others have shown that cocaine exposure in vivo reduces the strength of GABAergic inhibition to VTA dopamine neurons19,29,30. The selective PDE4 inhibitor rolipram blocks the cocaine-induced reduction in the mean frequency and amplitude of spontaneous IPSCs (sIPSCs) in VTA dopamine neurons17. Having shown that pretreatment with resveratrol attenuated cocaine CPP, we next investigated whether cocaine CPP was associated with changes in sIPSCs and whether resveratrol pretreatments altered cocaine-induced effects on sIPSCs. One day after the CPP test shown in Fig. 4, the mice were sacrificed and midbrain slices were prepared. sIPSCs were recorded from VTA dopamine neurons in these four groups of mice. Two-way ANOVA revealed that cocaine conditioning and resveratrol pretreatments had significant effects on the mean frequency of sIPSCs (cocaine: F (1,49) = 25.488, p < 0.001; resveratrol: F (1,49) = 33.455, p < 0.001; cocaine × resveratrol interaction: F (1,49) = 16.280, p < 0.001; Fig. 5a,b), and the mean amplitude of sIPSCs (cocaine: F (1,49) = 10.573, p = 0.002; resveratrol: F (1,49) = 19.053, p < 0.001; cocaine × resveratrol interaction: F (1,49) = 8.183, p = 0.006; Fig. 5a,c). Tukey’s post hoc tests indicated that cocaine conditioning led to significant decreases in the mean frequency (p < 0.001; Fig. 5b) and amplitude of sIPSCs (p < 0.001; Fig. 5c), which was blocked by resveratrol pretreatment (p < 0.001; Fig. 5b,c). The cumulative distribution for inter-event intervals of sIPSCs was shifted to the right (i.e., longer interval and less frequent) in the vehicle/cocaine group (p < 0.001; Fig. 5d), and this shift was blocked by resveratrol pretreatments (p < 0.001; Fig. 5d). The cumulative distribution for the amplitude of sIPSCs was shifted to the left (i.e., smaller value) in the vehicle/cocaine group (p < 0.001; Fig. 5e), and this shift was blocked by resveratrol pretreatments (p < 0.001; Fig. 5e). Together, these results indicate that cocaine conditioning led to a reduction of the frequency and amplitude of sIPSCs, and that this reduction was blocked by resveratrol pretreatments.
Discussion
The present study has shown that resveratrol increased cAMP levels in midbrain slices. In addition, we have shown that resveratrol potentiated both GABAA- and GABAB-mediated IPSCs via cAMP/PKA-dependent mechanisms, and blocked I-LTD in VTA dopamine neurons. Further, resveratrol attenuated cocaine CPP and the cocaine conditioning-induced decrease in sIPSCs in VTA dopamine neurons. Together, these results suggest that resveratrol attenuates cocaine-induced inhibitory synaptic plasticity and rewarding effects.
A recent study has shown that resveratrol raises both cAMP and cGMP levels in Hela cells via inhibition of PDE1, PDE3 and PDE47. To determine whether resveratrol has similar effects in the brain, we determined whether it enhanced cAMP levels in midbrain slices. The slices were incubated with vehicle, resveratrol, rolipram alone or in combination with the adenylyl cyclase activator FSK, and cAMP levels in midbrain slices were measured using an ELISA kit. We found that resveratrol, rolipram, and forskolin by themselves increased cAMP levels compared with that of vehicle, and that resveratrol or rolipram potentiated the forskolin-induced increase in cAMP. The latter finding is consistent with the idea that resveratrol and rolipram are PDE inhibitors, but not adenylyl cyclase activators7.
Bath application of resveratrol caused a significant increase in the amplitude of evoked GABAA-mediated IPSCs, which was accompanied by a decrease in the PPR. A change in the PPR suggests a change in presynaptic neurotransmitter release probability21. These results suggest that resveratrol induced an increase in GABA release in the VTA. The effect of resveratrol on GABAA-IPSCs was blocked by the PKA inhibitor H89. Drugs that enhance cAMP/PKA signaling enhance glutamate or GABA release at central synapses22–25, whereas drugs that inhibit cAMP/PKA signaling decrease neurotransmitter release31,32. Thus, resveratrol enhances GABAA-mediated IPSCs through a PKA-dependent potentiation of presynaptic GABA release. We have shown previously that the combination of 10 Hz stimulation with a low concentration of cocaine induces endocannabinoid-mediated I-LTD in VTA dopamine neurons19, and this I-LTD is dependent on cAMP/PKA signaling20. The present study indicates that resveratrol blocked I-LTD in VTA dopamine neurons. Since a decrease in presynaptic cAMP/PKA activity is required for I-LTD induction20,26, it is likely that resveratrol blocked I-LTD via an enhancement of presynaptic cAMP/PKA signaling.
While GABAA-mediated IPSCs can be induced by single synaptic stimulation, GABAB-mediated IPSCs often require repetitive synaptic stimulation at high-frequency27. GABAB receptors are located at perisynaptic sites and high-frequency stimulation causes spillover of GABA to activate these receptors27. Resveratrol also produced an enhancement of GABAB-mediated IPSCs in VTA dopamine neurons, and this effect was blocked by the PKA inhibitor H89. The similar enhancement of GABAA- and GABAB-mediated IPSCs further suggests that resveratrol enhances presynaptic GABA release in VTA dopamine neurons (Fig. 6). Genetic deletion of GABAB receptors from dopamine neurons in adult mice increased cocaine-induced locomotion33. GABAB agonists and positive allosteric modulators have been shown to reduce behavioral effects of drugs of abuse including cocaine34. Enhancing GABAB receptor-mediated inhibition may also contribute to the inhibitory effects of resveratrol on cocaine CPP (see below).
The effects of resveratrol on IPSCs should depend on where the PDEs are expressed. The distribution of PDE4 in the brain has been well-studied relative to other types of PDEs. PDE4 has four isoforms: PDE4A, PDE4B, PDE4C, and PDE4D35,36. PDE4A, PDE4B, and PDE4D are the main isoforms expressed in the rodent brain37,38. PDE4A is the most abundant isoform expressed in the VTA, but its expression in different cell types of the VTA has not been studied38. We suspect that resveratrol inhibits PDE4A on VTA GABA neurons, leading to an enhancement of GABA release.
PDE inhibitors reduce drug intake and/or drug seeking for psychostimulants, alcohol, and opioids11,12. The selective PDE4 inhibitor rolipram significantly reduces cocaine-induced increases in locomotor activity, behavioral sensitization, CPP and self-administration13–17. The present study has shown that pretreatments with resveratrol attenuated cocaine CPP. This finding stands in contrast with two previous studies. Resveratrol has been shown to enhance cocaine CPP in mice by activating sirtuins5. However, another study has shown that it is ineffective in altering CPP in rats6. The dose (20 mg/kg, i.p.) of resveratrol used here was the same as that used in the mouse study5, while doses of 20–110 mg/kg were used in the rat study6. The reason for the discrepancy among these studies is not yet clear but could not be attributable to the doses used.
In addition, we found that resveratrol pretreatments blocked the cocaine conditioning-induced reduction of GABAergic inhibition in VTA dopamine neurons. Cocaine conditioning led to decreases in the frequency and amplitude of sIPSCs, and these decreases were blocked in mice that received resveratrol pretreatments. Our previous studies suggest that endocannabinoid-mediated I-LTD provides a putative mechanism for the cocaine-induced reduction of GABAergic inhibition in VTA dopamine neurons19. Resveratrol may block the cocaine-induced reduction of GABAergic inhibition via a mechanism of I-LTD blockade.
In summary, we have shown that resveratrol enhances GABAA- and GABAB-mediated IPSCs in VTA dopamine neurons. Additionally, it blocked endocannabinoid-mediated I-LTD. Finally, we showed that resveratrol attenuated cocaine CPP and abolished the cocaine-induced reduction of GABAergic inhibition. These results provide evidence that resveratrol blocks cocaine-induced synaptic plasticity in VTA dopamine neurons and drug-cue associative learning.
Methods and Materials
Animals
Male C57BL/6J mice (8–10 weeks old) were used for brain slice electrophysiological recordings, behavior experiments and enzyme-linked immunosorbent assay (ELISA). Animal maintenance and use were in accordance with protocols approved by the Institutional Animal Care and Use Committee of the Medical College of Wisconsin.
Brain slice preparation
Midbrain slices (200 μm) from male C57BL/6J mice were prepared as described previously39,40. Mice were anaesthetized by isoflurane inhalation and decapitated. The whole brain was quickly removed and embedded in 3% low-melting-point agarose. Horizontal midbrain slices (200 μm thick) were cut using a vibrating slicer (Leica VT1200s, Nussloch, Germany), using choline-based solution containing (in mM): 110 choline chloride, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 7 MgSO4, 23 NaHCO3, 25 glucose, 11.6 sodium ascorbate, and 3.1 sodium pyruvate at room temperature. The slices containing the ventral tegmental area of the midbrain (VTA) were incubated in the sucrose-based solution containing (in mM): 78 NaCl, 68 sucrose, 23 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 2 MgCl2 and 25 glucose for 30–40 minutes at room temperature. Then, the slices were allowed to recover in the ACSF containing (in mM): 119 NaCl, 2.5 KCl, 2.5 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 23 NaHCO3, and 10 glucose.
Electrophysiological recordings
Whole-cell patch-clamp recording was made on VTA dopamine neurons using patch clamp amplifiers (Multiclamp 700B) under infrared-differential interference contrast (DIC) microscopy. Data acquisition and analysis were performed using DigiData 1440 A or DigiData 1550B digitizers and analysis software pClamp 10 (Molecular Devices). Signals were filtered at 2 kHz and sampled at 10 kHz. Dopamine neurons in the VTA were identified by long duration (>1.5 ms) of spontaneous action potentials in cell-attached configuration41 and the presence of large Ih currents, rhythmic firing at low frequency and prominent afterhyperpolarization in whole-cell mode29,42,43. For recording evoked inhibitory postsynaptic currents (IPSCs), electrical stimulation was delivered by a bipolar tungsten stimulation electrode (WPI) that was placed at fixed distance (~150 μm) rostral to the soma of recorded dopamine neuron. For recordings of GABAA receptor-mediated IPSCs and spontaneous IPSCs, glass pipettes (3–5 MΩ) were filled with an internal solution containing (in mM): 90 K-gluconate, 50 KCl, 10 HEPES, 0.2 EGTA, 2 MgCl2, 4 Mg-ATP, 0.3 Na2GTP, and 10 Na2-phosphocreatine (pH 7.2 with KOH). To isolate GABAA receptor-mediated IPSCs, CNQX (20 µM), D-AP5 (50 µM) and CGP 55845 (1 µM) were present in the ACSF to block AMPA receptors, NMDA receptors and GABAB receptors, respectively. For recording GABAB receptor-mediated IPSCs, glass pipettes (3–5 MΩ) were filled with an internal solution containing (in mM): 140 K-gluconate, 5 KCl, 10 HEPES, 0.2 EGTA, 2 MgCl2, 4 Mg-ATP, 0.3 Na2GTP, and 10 Na2-phosphocreatine (pH 7.2 with KOH). Neurons were voltage-clamped at −70 mV for GABAA-IPSCs and −55 mV for GABAB-IPSCs. The GABAB receptor-mediated IPSCs were evoked by five stimuli (0.3 ms) at 50 Hz. To isolate GABAB receptor-mediated IPSCs, picrotoxin (100 μM), CNQX (10 μM), MK-801 (10 μM), sulpiride (1 μM), and CPCCOEt (100 µM) were added in the ACSF to block GABAA receptors, AMPA receptors, NMDA receptors and group I metabotropic glutamate receptors (mGluRs), respectively. Series resistance (15–30 MΩ) was monitored throughout all recordings, and data were discarded if the resistance changed by more than 20%. All recordings were performed at 32 ± 1 °C by using an automatic temperature controller (Warner Instruments, Inc).
The cAMP assay
cAMP levels were measured with the mouse cAMP ELISA kit (Enzo Life Sciences), according to the manufacturer’s protocol. Briefly, horizontal midbrain slices containing the VTA were prepared as described above. Slices were treated with vehicle, resveratrol (100 µM), rolipram (1 µM) and/or the adenylyl cyclase activator forskolin (10 µM) for 30 min, washed, frozen in liquid nitrogen and then homogenized in ice-cold 0.1 M HCl. The homogenates were centrifuged at 13, 000 × g for 50 min at 4 °C to pellet debris. The supernatants were collected for ELISA assay. Absorbance was read at 405 nm with an ELX800 Universal Microplate Reader (Bio-TEK Instruments). Finally, the cAMP level was normalized to the total protein concentration, which was assayed using a BCA method.
Conditioned place preference (CPP)
CPP experiments were performed based on previously published procedures16,44 with minor modifications. The CPP protocol consisted of the following three sections: (1) pre-test (day 1): mice were placed in the middle chamber of the three-chamber conditioning apparatus (Med Associates, St Albans, Vermont) and allowed to explore three chambers freely for 20 min, with time spent in each chamber recorded. Mice showing unconditioned side preference (> = 180 s disparity) were excluded. (2) Conditioning (day 2–7): Cocaine conditioning. On days 2, 4 and 6, mice were injected with cocaine (15 mg/kg, i.p.) and confined to one chamber for 30 min; On day 3, 5 and 7, mice were injected with saline (0.9% NaCl, 2 ml/kg, i.p.) and confined to one chamber for 30 min. Saline conditioning. Mice were injected with saline (0.9% NaCl, 2 ml/kg, i.p.) daily and were confined to one chamber for 30 min on days 3, 5 and 7 and were confined to the opposite chamber for 30 min on days 2, 4 and 6. (3) CPP test (day 8): All of the mice were allowed to explore freely for 20 min between the two sides, and time spent on each side was recorded. Subgroups of mice also received i.p. infusions of vehicle (5% DMSO in saline) or resveratrol (20 mg/kg) 30 min before each cocaine or saline injections.
Statistics
Data are present as mean ± SEM. The magnitude of I-LTD and evoked IPSCs was calculated as we have described previously19,45. The frequency and amplitude of sIPSCs were analyzed using Minianalysis (Synaptosoft Inc.) as we have described17. The paired-pulse ration (PPR) was calculated as the ratio of the amplitude of the second IPSCs to that of the first IPSCs. CPP scores were calculated as the time spent in the cocaine-paired chamber minus the time spent in the saline-paired chamber. Data sets were compared with either Student’s t-test (I-LTD, evoked IPSCs amplitude and PPR) or two-way ANOVA (the frequency and amplitude of sIPSCs and CPP scores) followed by Tukey post hoc analysis. Paired t-test was used for before and after comparison from the same cells, while t-test was used for different data set comparison. Results were considered to be significant at p < 0.05.
Electronic supplementary material
Untitled section
Acknowledgements
This research was funded by NIH Grants DA035217 and MH101146 (Q.-s.L.) and National Natural Science Foundation of China 31571229 (Z.L.). It was also partially funded through the Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin endowment at the Medical College of Wisconsin. We thank Casey Vickstrom for critical reading of the manuscript, and Xiaojie Liu for preparing Figure 6.
Untitled section
Competing Interests
The authors declare that they have no competing interests.
Footnotes
Footnote Group
Contributor Information
Li Zhao, Email: zhaolispring@126.com.
Qing-song Liu, Email: qsliu@mcw.edu.
References
Untitled section
References
- 1.Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mechanisms of ageing and development. 2010;131:261–269. doi: 10.1016/j.mad.2010.02.007.
- 2.Howitz KT, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191–196. doi: 10.1038/nature01960.
- 3.Shuto T, et al. Acute effects of resveratrol to enhance cocaine-induced dopamine neurotransmission in the striatum. Neuroscience letters. 2013;542:107–112. doi: 10.1016/j.neulet.2013.02.050.
- 4.Miller DK, Oelrichs CE, Sage AS, Sun GY, Simonyi A. Repeated resveratrol treatment attenuates methamphetamine-induced hyperactivity and [3H]dopamine overflow in rodents. Neuroscience letters. 2013;554:53–58. doi: 10.1016/j.neulet.2013.08.051.
- 5.Renthal W, et al. Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtuins. Neuron. 2009;62:335–348. doi: 10.1016/j.neuron.2009.03.026.
- 6.Hu P, et al. Resveratrol fails to affect cocaine conditioned place preference behavior, but alleviates anxiety-like behaviors in cocaine withdrawn rats. Psychopharmacology. 2016;233:1279–1287. doi: 10.1007/s00213-016-4210-4.
- 7.Park SJ, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148:421–433. doi: 10.1016/j.cell.2012.01.017.
- 8.Conti M, et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. The Journal of biological chemistry. 2003;278:5493–5496. doi: 10.1074/jbc.R200029200.
- 9.Zhang HT. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Current pharmaceutical design. 2009;15:1688–1698. doi: 10.2174/138161209788168092.
- 10.Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacology & therapeutics. 2006;109:366–398. doi: 10.1016/j.pharmthera.2005.07.003.
- 11.Wen RT, Feng WY, Liang JH, Zhang HT. Role of phosphodiesterase 4-mediated cyclic AMP signaling in pharmacotherapy for substance dependence. Current pharmaceutical design. 2015;21:355–364. doi: 10.2174/1381612820666140826114412.
- 12.Olsen, C. M. & Liu, Q. S. Phosphodiesterase 4 inhibitors and drugs of abuse: current knowledge and therapeutic opportunities. Frontiers in Biology, 10.1007/s11515-016-1424-0 (2016).
- 13.Knapp CM, Foye MM, Ciraulo DA, Kornetsky C. The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram, block the initiation of cocaine self-administration. Pharmacology, biochemistry, and behavior. 1999;62:151–158. doi: 10.1016/S0091-3057(98)00154-3.
- 14.Thompson BE, Sachs BD, Kantak KM, Cherry JA. The Type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice. The European journal of neuroscience. 2004;19:2561–2568. doi: 10.1111/j.0953-816X.2004.03357.x.
- 15.Janes AC, Kantak KM, Cherry JA. The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens. Psychopharmacology. 2009;206:177–185. doi: 10.1007/s00213-009-1594-4.
- 16.Zhong P, et al. Phosphodiesterase 4 inhibition impairs cocaine-induced inhibitory synaptic plasticity and conditioned place preference. Neuropsychopharmacology. 2012;37:2377–2387. doi: 10.1038/npp.2012.93.
- 17.Liu X, Zhong P, Vickstrom C, Li Y, Liu QS. PDE4 Inhibition Restores the Balance Between Excitation and Inhibition in VTA Dopamine Neurons Disrupted by Repeated In Vivo Cocaine Exposure. Neuropsychopharmacology. 2017 doi: 10.1038/npp.2017.96.
- 18.Wang G, Amato S, Gilbert J, Man HY. Resveratrol up-regulates AMPA receptor expression via AMP-activated protein kinase-mediated protein translation. Neuropharmacology. 2015;95:144–153. doi: 10.1016/j.neuropharm.2015.03.003.
- 19.Pan B, Hillard CJ, Liu QS. Endocannabinoid signaling mediates cocaine-induced inhibitory synaptic plasticity in midbrain dopamine neurons. J Neurosci. 2008;28:1385–1397. doi: 10.1523/JNEUROSCI.4033-07.2008.
- 20.Pan B, Hillard CJ, Liu QS. D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling. J Neurosci. 2008;28:14018–14030. doi: 10.1523/JNEUROSCI.4035-08.2008.
- 21.Zucker RS, Regehr WG. Short-term synaptic plasticity. Annual review of physiology. 2002;64:355–405. doi: 10.1146/annurev.physiol.64.092501.114547.
- 22.Chavez-Noriega LE, Stevens CF. Increased transmitter release at excitatory synapses produced by direct activation of adenylate cyclase in rat hippocampal slices. J Neurosci. 1994;14:310–317. doi: 10.1523/JNEUROSCI.14-01-00310.1994.
- 23.Chen C, Regehr WG. The mechanism of cAMP-mediated enhancement at a cerebellar synapse. J Neurosci. 1997;17:8687–8694. doi: 10.1523/JNEUROSCI.17-22-08687.1997.
- 24.Capogna M, Gahwiler BH, Thompson SM. Presynaptic enhancement of inhibitory synaptic transmission by protein kinases A and C in the rat hippocampus in vitro. J Neurosci. 1995;15:1249–1260. doi: 10.1523/JNEUROSCI.15-02-01249.1995.
- 25.Kaneko M, Takahashi T. Presynaptic mechanism underlying cAMP-dependent synaptic potentiation. J Neurosci. 2004;24:5202–5208. doi: 10.1523/JNEUROSCI.0999-04.2004.
- 26.Chiu CQ, Puente N, Grandes P, Castillo PE. Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex. J Neurosci. 2010;30:7236–7248. doi: 10.1523/JNEUROSCI.0736-10.2010.
- 27.Luscher C, Slesinger PA. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nature reviews. 2010;11:301–315. doi: 10.1038/nrn2834.
- 28.Ford CP, Mark GP, Williams JT. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci. 2006;26:2788–2797. doi: 10.1523/JNEUROSCI.4331-05.2006.
- 29.Liu QS, Pu L, Poo MM. Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons. Nature. 2005;437:1027–1031. doi: 10.1038/nature04050.
- 30.Bocklisch C, et al. Cocaine disinhibits dopamine neurons by potentiation of GABA transmission in the ventral tegmental area. Science (New York, N.Y. 2013;341:1521–1525. doi: 10.1126/science.1237059.
- 31.Price CJ, Karayannis T, Pal BZ, Capogna M. Group II and III mGluRs-mediated presynaptic inhibition of EPSCs recorded from hippocampal interneurons of CA1 stratum lacunosum moleculare. Neuropharmacology. 2005;49(Suppl 1):45–56. doi: 10.1016/j.neuropharm.2005.05.009.
- 32.Marty A, Glitsch M, Kondo S, Llano I. Cyclic AMP-regulated GABA release at inhibitory synapses in rat cerebellar slices. Journal of physiology, Paris. 1996;90:327–328. doi: 10.1016/S0928-4257(97)87909-0.
- 33.Edwards NJ, et al. Circuit specificity in the inhibitory architecture of the VTA regulates cocaine-induced behavior. Nat Neurosci. 2017;20:438–448. doi: 10.1038/nn.4482.
- 34.Filip M, et al. GABAB receptors as a therapeutic strategy in substance use disorders: focus on positive allosteric modulators. Neuropharmacology. 2015;88:36–47. doi: 10.1016/j.neuropharm.2014.06.016.
- 35.Wang ZZ, Zhang Y, Zhang HT, Li YF. Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases. Current pharmaceutical design. 2015;21:303–316. doi: 10.2174/1381612820666140826115559.
- 36.MacKenzie SJ, Houslay MD. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. The Biochemical journal. 2000;347:571–578. doi: 10.1042/bj3470571.
- 37.Johansson EM, Reyes-Irisarri E, Mengod G. Comparison of cAMP-specific phosphodiesterase mRNAs distribution in mouse and rat brain. Neurosci Lett. 2012;525:1–6. doi: 10.1016/j.neulet.2012.07.050.
- 38.Perez-Torres S, et al. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. Journal of chemical neuroanatomy. 2000;20:349–374. doi: 10.1016/S0891-0618(00)00097-1.
- 39.Liu X, et al. Epac Signaling Is Required for Cocaine-Induced Change in AMPA Receptor Subunit Composition in the Ventral Tegmental Area. J Neurosci. 2016;36:4802–4815. doi: 10.1523/JNEUROSCI.3186-15.2016.
- 40.Tong J, et al. The Epac-Phospholipase Cepsilon Pathway Regulates Endocannabinoid Signaling and Cocaine-Induced Disinhibition of Ventral Tegmental Area Dopamine Neurons. J Neurosci. 2017;37:3030–3044. doi: 10.1523/JNEUROSCI.2810-16.2017.
- 41.Chieng B, Azriel Y, Mohammadi S, Christie MJ. Distinct cellular properties of identified dopaminergic and GABAergic neurons in the mouse ventral tegmental area. J Physiol. 2011;589:3775–3787. doi: 10.1113/jphysiol.2011.210807.
- 42.Jones S, Kauer JA. Amphetamine depresses excitatory synaptic transmission via serotonin receptors in the ventral tegmental area. J Neurosci. 1999;19:9780–9787. doi: 10.1523/JNEUROSCI.19-22-09780.1999.
- 43.Johnson SW, North RA. Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J Physiol. 1992;450:455–468. doi: 10.1113/jphysiol.1992.sp019136.
- 44.Zhong P, et al. BDNF interacts with endocannabinoids to regulate cocaine-induced synaptic plasticity in mouse midbrain dopamine neurons. J Neurosci. 2015;35:4469–4481. doi: 10.1523/JNEUROSCI.2924-14.2015.
- 45.Yu F, et al. Metabotropic glutamate receptor I (mGluR1) antagonism impairs cocaine-induced conditioned place preference via inhibition of protein synthesis. Neuropsychopharmacology. 2013;38:1308–1321. doi: 10.1038/npp.2013.29.